Insect Sting Anaphylaxis-Or Mastocytosis-Or Something Else?


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
04 2019
Historique:
received: 12 11 2018
revised: 07 01 2019
accepted: 09 01 2019
entrez: 10 4 2019
pubmed: 10 4 2019
medline: 25 7 2020
Statut: ppublish

Résumé

Insect sting anaphylaxis and mast cell disorders are intertwined in a specific and unusual way. There may be specific subsets of clonal mast cell disorders that are predisposed to sting anaphylaxis. The clinical characteristics of the sting reactions should raise suspicion of underlying mastocytosis (eg, hypotension without hives especially in a male). A baseline serum tryptase level is helpful in the evaluation of patients with insect sting anaphylaxis because it correlates with important risks for these patients, and they have a high frequency of abnormally elevated baseline levels. Elevated baseline serum tryptase level has been reported to correlate with clonal mast cell disease in patients with insect sting anaphylaxis but may also indicate one of several possible underlying syndromes, including mast cell activation syndrome (MCAS), familial hypertryptasemia, and idiopathic anaphylaxis. There is some overlap in these conditions, so it is important to evaluate the clinical pattern at presentation as well as laboratory markers, and to consider bone marrow biopsy to make a final and specific diagnosis of clonal mast cell disease. The presence of venom-IgE does not prove that the patient's previous sting reactions were IgE-mediated, but even low levels of venom-IgE in patients with mastocytosis predispose to severe sting anaphylaxis. Evaluation of all these possible factors will affect the recommendation for venom immunotherapy.

Identifiants

pubmed: 30961837
pii: S2213-2198(19)30066-2
doi: 10.1016/j.jaip.2019.01.014
pii:
doi:

Substances chimiques

Arthropod Venoms 0
Histamine H1 Antagonists 0
Histamine H2 Antagonists 0
Wasp Venoms 0
Immunoglobulin E 37341-29-0
KIT protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-kit EC 2.7.10.1
Tryptases EC 3.4.21.59

Types de publication

Case Reports Journal Article Research Support, N.I.H., Intramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1117-1123

Informations de copyright

Copyright © 2019 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Auteurs

David B K Golden (DBK)

Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, Md. Electronic address: dgolden1@jhmi.edu.

Melody C Carter (MC)

Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH